A genome-wide CRISPR screening approach identified a druggable Wnt-FZD5 signaling circuit as a critical vulnerability specific to RNF43-mutant pancreatic tumors, revealing a potential therapeutic strategy for this genetically defined subset of pancreatic cancers [143]. Here, FZD5 is linked to pancreatic neoplasm.